US 12,084,682 B2
Gene-regulating compositions and methods for improved immunotherapy
Micah Benson, Lexington, MA (US); Jason J. Merkin, Lexington, MA (US); Gregory V. Kryukov, Lexington, MA (US); Solomon Martin Shenker, Lexington, MA (US); Michael R. Schlabach, Lexington, MA (US); Noah Jacob Tubo, Lexington, MA (US); and James Martin Kaberna, II, Lexington, MA (US)
Assigned to KSQ Therapeutics, Inc., Lexington, MA (US)
Filed by KSQ Therapeutics, Inc., Lexington, MA (US)
Filed on Dec. 13, 2022, as Appl. No. 18/065,580.
Application 18/065,580 is a continuation of application No. 17/707,725, filed on Mar. 29, 2022.
Application 17/707,725 is a continuation of application No. 16/951,310, filed on Nov. 18, 2020, granted, now 11,332,713.
Application 16/951,310 is a continuation of application No. 16/354,100, filed on Mar. 14, 2019, granted, now 11,261,428.
Claims priority of provisional application 62/804,261, filed on Feb. 12, 2019.
Claims priority of provisional application 62/790,192, filed on Jan. 9, 2019.
Claims priority of provisional application 62/790,179, filed on Jan. 9, 2019.
Claims priority of provisional application 62/768,441, filed on Nov. 16, 2018.
Claims priority of provisional application 62/768,428, filed on Nov. 16, 2018.
Claims priority of provisional application 62/736,185, filed on Sep. 25, 2018.
Claims priority of provisional application 62/692,010, filed on Jun. 29, 2018.
Claims priority of provisional application 62/692,016, filed on Jun. 29, 2018.
Claims priority of provisional application 62/643,584, filed on Mar. 15, 2018.
Claims priority of provisional application 62/643,578, filed on Mar. 15, 2018.
Prior Publication US 2023/0340411 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0783 (2010.01); A61K 35/17 (2015.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01)
CPC C12N 5/0636 (2013.01) [A61K 35/17 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 16/2803 (2013.01); C07K 16/2863 (2013.01); C07K 16/32 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/113 (2013.01); C12N 15/1135 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2319/30 (2013.01); C12N 2310/122 (2013.01); C12N 2310/14 (2013.01); C12N 2310/20 (2017.05); C12N 2310/531 (2013.01); C12N 2800/80 (2013.01)] 7 Claims
 
1. A method of treating cancer in a subject in need thereof, the method comprising: administering to the subject a composition comprising a therapeutically effective amount of modified human tumor infiltrating lymphocytes (TILs) that have been modified in vitro to comprise an insertion, deletion, or mutation in an endogenous SOCS1 gene, wherein endogenous SOCS1 gene expression is reduced in the modified human TILs, relative to unmodified human TILs obtained from the subject, and the modified human TILs are autologous to the subject.